Q3 2025 Earnings Call Transcript November 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...
Q3 2025 Earnings Call November 17, 2025 8:30 AM ESTCompany ParticipantsMatthew Duffy - Chief Business Officer & ...
Earlier this year, researchers at Children's Hospital of Philadelphia and Penn created a first-of-its-kind drug customized to ...
A bill aimed at streamlining the process of making certain prescription medicines available over the counter has been enacted ...
Patent reforms could address a problem that’s been driving rising prescription drug costs and create a more competitive ...
Clinical Trials Arena on MSN
FDA unveils new pathway to usher bespoke therapies to market
The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...
The “plausible mechanism” pathway, outlined by Martin Makary and Vinay Prasad, is designed to help accelerate treatments ...
The amount New York receives will likely depend in part on whether the state implements policies pushed by the Trump administration.
The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, ...
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback